Christopher W. Ryan, M.D.

  • Professor of Medicine, School of Medicine

Biography

Dr. Ryan is a clinical researcher whose work focuses on testing new agents for renal carcinoma and sarcomas. He is particularly interested in clinical trial design and novel endpoints. He is currently studying the utility of dynamic contrast enhanced MRI data as a biomarker for activity of novel agents in the treatment of soft tissue sarcomas. His clinical practice is centered around an active trial portfolio.

Education and training

  • Residency

    • Internal medicine, University of Chicago, 1997

  • Fellowship

    • Hematology/oncology, University of Chicago, 2000

  • Certifications

    • American Board of Internal Medicine (medical oncology), 2000

Memberships and associations:

  • American Society of Clinical Oncology

Publications

Elsevier pure profile

Publications

  • A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib

    Cancer
    1. Jayesh Desai
    2. Andrew J. Wagner
    3. Irene Carrasco Garcia
    4. Marilena Cesari
    5. Michael Gordon
    6. Chia Chi Lin
    7. Zsuzsanna Papai
    8. Christopher W. Ryan
    9. William D. Tap
    10. Jonathan C. Trent
    11. Hans Gelderblom
    12. Peter Grimison
    13. Antonio López Pousa
    14. Brian A. Van Tine
    15. Maria Rubinacci
    16. Dong Dai
    17. Abdul Waheed Rajper
    18. Kristen Tecson
    19. Margaret Wooddell
    20. Silvia Stacchiotti

  • A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609

    Clinical Cancer Research
    1. Young Kwang Chae
    2. Lucy Corthell
    3. Sandip Pravin Patel
    4. Robert Edwards
    5. Jennifer M. Scalici
    6. Hye Sung Kim
    7. Liam Il Young Chung
    8. Megan Othus
    9. Christine M. McLeod
    10. Helen X. Chen
    11. Elad Sharon
    12. Howard Streicher
    13. Christopher W. Ryan
    14. Charles D. Blanke
    15. Razelle Kurzrock

  • Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma

    npj Precision Oncology
    1. Sandip P. Patel
    2. Eleanor Cano-Linson
    3. Young Kwang Chae
    4. Shiruyeh Schokrpur
    5. Christopher D. Lao
    6. Benjamin C. Powers
    7. Adrienne I. Victor
    8. Adedayo A. Onitilo
    9. Sarah Shin
    10. Naoko Takebe
    11. Sara Threlkel
    12. Christine M. McLeod
    13. Helen X. Chen
    14. Elad Sharon
    15. Megan Othus
    16. Christopher W. Ryan
    17. Charles D. Blanke
    18. Razelle Kurzrock

  • Adjuvant Everolimus in Non-Clear Cell Renal Cell Carcinoma

    JAMA Network Open
    1. Shuchi Gulati
    2. Catherine Tangen
    3. Christopher W. Ryan
    4. Ulka N. Vaishampayan
    5. Brian M. Shuch
    6. Pedro C. Barata
    7. Deepak K. Pruthi
    8. Cristiane D. Bergerot
    9. Abhishek Tripathi
    10. Seth P. Lerner
    11. Ian M. Thompson
    12. Primo N. Lara
    13. Sumanta K. Pal

  • Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology

    European Urology
    1. Primo N. Lara
    2. Catherine Tangen
    3. Elisabeth I. Heath
    4. Shuchi Gulati
    5. Mark N. Stein
    6. Maxwell Meng
    7. Ajjai Shivaram Alva
    8. Sumanta K. Pal
    9. Igor Puzanov
    10. Joseph I. Clark
    11. Toni K. Choueiri
    12. Neeraj Agarwal
    13. Robert Uzzo
    14. Naomi B. Haas
    15. Timothy W. Synold
    16. Melissa Plets
    17. Ulka N. Vaishampayan
    18. Brian M. Shuch
    19. Seth Lerner
    20. Ian M. Thompson
    21. Christopher W. Ryan

  • A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia

    Clinical Cancer Research
    1. Sandip P. Patel
    2. Megan Othus
    3. Young Kwang Chae
    4. Michael J. Dennis
    5. Sarah Gordon
    6. David Mutch
    7. Wolfram Samlowski
    8. William R. Rusty Robinson
    9. Elad Sharon
    10. Christopher Ryan
    11. Gabby Lopez
    12. Melissa Plets
    13. Charles Blanke
    14. Razelle Kurzrock

  • Mixed Adenosquamous Cell Carcinoma of the Prostate with Paired Sequencing on the Primary and Liver Metastasis

    Current Oncology
    1. Emmanuella Oyogoa
    2. Maya Sonpatki
    3. Brian T. Brinkerhoff
    4. Nicole Andeen
    5. Haley Meyer
    6. Christopher Ryan
    7. Alexandra O. Sokolova

  • Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609

    Journal for immunotherapy of cancer
    1. Young Kwang Chae
    2. Megan Othus
    3. Sandip Patel
    4. Benjamin Powers
    5. Chung Tsen Hsueh
    6. Rangaswamy Govindarajan
    7. Silvana Bucur
    8. Hye Sung Kim
    9. Liam IL Young Chung
    10. Christine McLeod
    11. Helen X. Chen
    12. Elad Sharon
    13. Howard Streicher
    14. Christopher W. Ryan
    15. Charles Blanke
    16. Razelle Kurzrock

  • Phase II basket trial of Dual AntiCTLA-4 and Anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609

    Journal for immunotherapy of cancer
    1. Sandip P. Patel
    2. Megan Othus
    3. Young Kwang Chae
    4. Tridu Huynh
    5. Benjamin Tan
    6. Timothy Kuzel
    7. Christine McLeod
    8. Gabby Lopez
    9. Helen X. Chen
    10. Elad Sharon
    11. Howard Streicher
    12. Christopher W. Ryan
    13. Charles Blanke
    14. Razelle Kurzrock

  • Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience

    Therapeutic Advances in Medical Oncology
    1. Young Kwang Chae
    2. Megan Othus
    3. Sandip Pravin Patel
    4. David E. Gerber
    5. Tawee Tanvetyanon
    6. Hye Sung Kim
    7. Liam Il Young Chung
    8. Christine M. McLeod
    9. Gabby Lopez
    10. Helen X. Chen
    11. Elad Sharon
    12. Howard Streicher
    13. Cristopher W. Ryan
    14. Charles D. Blanke
    15. Razelle Kurzrock

  • Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy

    Journal of Clinical Oncology
    1. Leonard J. Appleman
    2. Se Eun Kim
    3. Wayne B. Harris
    4. Sumanta K. Pal
    5. Michael R. Pins
    6. Jill Kolesar
    7. Neeraj Agarwal
    8. Rahul A. Parikh
    9. Daniel A. Vaena
    10. Christopher W. Ryan
    11. Mehmood Hashmi
    12. Brian A. Costello
    13. David Cella
    14. Janice P. Dutcher
    15. Robert S. Dipaola
    16. Naomi B. Haas
    17. Lynne I. Wagner
    18. Michael A. Carducci

  • SWOG 1609 cohort 48

    Cancer
    1. Sandip P. Patel
    2. Elizabeth Guadarrama
    3. Young Kwang Chae
    4. Michael J. Dennis
    5. Benjamin C. Powers
    6. Chih Yi Liao
    7. William A. Ferri
    8. Thomas J. George
    9. Elad Sharon
    10. Christopher W. Ryan
    11. Megan Othus
    12. Gabby Lopez
    13. Charles D. Blanke
    14. Razelle Kurzrock

  • SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors

    Clinical Cancer Research
    1. Young Kwang Chae
    2. Megan Othus
    3. Sandip Pravin Patel
    4. Kelly J. Wilkinson
    5. Emily M. Whitman-Purves
    6. Jayanthi Lea
    7. John M. Schallenkamp
    8. Nabil Adra
    9. Leonard J. Appleman
    10. Mitchell Alden
    11. Jessica Thomes Pepin
    12. John A. Ellerton
    13. Andrew Poklepovic
    14. Adam Walter
    15. Murtuza M. Rampurwala
    16. William R. Robinson
    17. Hye Sung Kim
    18. Liam Il Young Chung
    19. Christine M. McLeod
    20. Gabby Lopez
    21. Helen X. Chen
    22. Elad Sharon
    23. Howard Streicher
    24. Christopher W. Ryan
    25. Charles D. Blanke
    26. Razelle Kurzrock

  • Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST)

    The Lancet
    1. Christopher W. Ryan
    2. Catherine M. Tangen
    3. Elisabeth I. Heath
    4. Mark N. Stein
    5. Maxwell V. Meng
    6. Ajjai S. Alva
    7. Sumanta K. Pal
    8. Igor Puzanov
    9. Joseph I. Clark
    10. Toni K. Choueiri
    11. Neeraj Agarwal
    12. Robert G. Uzzo
    13. Naomi B. Haas
    14. Timothy W. Synold
    15. Melissa Plets
    16. Ulka N. Vaishampayan
    17. Brian M. Shuch
    18. Ian M. Thompson
    19. Primo N. Lara

  • A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone

    Cancer medicine
    1. Steven Attia
    2. Vanessa Bolejack
    3. Kristen N. Ganjoo
    4. Suzanne George
    5. Mark Agulnik
    6. Daniel Rushing
    7. Elizabeth T. Loggers
    8. Michael B. Livingston
    9. Jennifer Wright
    10. Sant P. Chawla
    11. Scott H. Okuno
    12. Denise K. Reinke
    13. Richard F. Riedel
    14. Lara E. Davis
    15. Christopher W. Ryan
    16. Robert G. Maki

  • A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma

    Clinical Genitourinary Cancer
    1. Zizhen Feng
    2. Brendan D. Curti
    3. David I. Quinn
    4. John M. Strother
    5. Zunqiu Chen
    6. Rebecca Agnor
    7. Tomasz M. Beer
    8. Christopher W. Ryan

  • A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era

    Clinical Genitourinary Cancer
    1. Brian A. Costello
    2. Nrupen A. Bhavsar
    3. Yousef Zakharia
    4. Sumanta K. Pal
    5. Ulka Vaishampayan
    6. Heather Jim
    7. Mayer N. Fishman
    8. Ana M. Molina
    9. Christos E. Kyriakopoulos
    10. Che Kai Tsao
    11. Leonard J. Appleman
    12. Benjamin A. Gartrell
    13. Arif Hussain
    14. Walter M. Stadler
    15. Neeraj Agarwal
    16. Russell K. Pachynski
    17. Thomas E. Hutson
    18. Hans J. Hammers
    19. Christopher W. Ryan
    20. Jack Mardekian
    21. Azah Borham
    22. Daniel J. George
    23. Michael R. Harrison

  • A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery

    European Journal of Cancer
    1. Evan Rosenbaum
    2. Rashmi Chugh
    3. Christopher W. Ryan
    4. Mark Agulnik
    5. Mohammed M. Milhem
    6. Suzanne George
    7. Robin L. Jones
    8. Bartosz Chmielowski
    9. Brian A. Van Tine
    10. Hussein Tawbi
    11. Anthony D. Elias
    12. William L. Read
    13. G. Thomas Budd
    14. Li Xuan Qin
    15. Eve T. Rodler
    16. Joe Hirman
    17. Paul Weiden
    18. Cathryn M. Bennett
    19. Philip O. Livingston
    20. Govind Ragupathi
    21. David Hansen
    22. Sandra P. D'Angelo
    23. William D. Tap
    24. Gary K. Schwartz
    25. Robert G. Maki
    26. Richard D. Carvajal

  • Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma

    Journal of Clinical Oncology
    1. Mrinal M. Gounder
    2. Albiruni Abdul Razak
    3. Neeta Somaiah
    4. Sant Chawla
    5. Javier Martin-Broto
    6. Giovanni Grignani
    7. Scott M. Schuetze
    8. Bruno Vincenzi
    9. Andrew J. Wagner
    10. Bartosz Chmielowski
    11. Robin L. Jones
    12. Richard F. Riedel
    13. Silvia Stacchiotti
    14. Elizabeth T. Loggers
    15. Kristen N. Ganjoo
    16. Axel Le Cesne
    17. Antoine Italiano
    18. Xavier Garcia Del Muro
    19. Melissa Burgess
    20. Sophie Piperno-Neumann
    21. Christopher Ryan
    22. Mary F. Mulcahy
    23. Charles Forscher
    24. Nicolas Penel
    25. Scott Okuno
    26. Anthony Elias
    27. Lee Hartner
    28. Tony Philip
    29. Thierry Alcindor
    30. Bernd Kasper
    31. Peter Reichardt
    32. Lore Lapeire
    33. Jean Yves Blay
    34. Christine Chevreau
    35. Claudia Maria Valverde Morales
    36. Gary K. Schwartz
    37. James L. Chen
    38. Hari Deshpande
    39. Elizabeth J. Davis
    40. Garth Nicholas
    41. Stefan Gröschel
    42. Helen Hatcher
    43. Florence Duffaud
    44. Antonio Casado Herráez
    45. Roberto Diaz Beveridge
    46. Giuseppe Badalamenti
    47. Mikael Eriksson
    48. Christian Meyer
    49. Margaret Von Mehren
    50. Brian A. Van Tine
    51. Katharina Götze
    52. Filomena Mazzeo
    53. Alexander Yakobson
    54. Aviad Zick
    55. Alexander Lee
    56. Anna Estival Gonzalez
    57. Andrea Napolitano
    58. Mark A. Dickson
    59. Dayana Michel
    60. Changting Meng
    61. Lingling Li
    62. Jianjun Liu
    63. Osnat Ben-Shahar
    64. Dane R. Van Domelen
    65. Christopher J. Walker
    66. Hua Chang
    67. Yosef Landesman
    68. Jatin J. Shah
    69. Sharon Shacham
    70. Michael G. Kauffman
    71. Steven Attia

  • Active surveillance of metastatic renal cell carcinoma

    Cancer
    1. Michael R. Harrison
    2. Brian A. Costello
    3. Nrupen A. Bhavsar
    4. Ulka Vaishampayan
    5. Sumanta K. Pal
    6. Yousef Zakharia
    7. Heather S.L. Jim
    8. Mayer N. Fishman
    9. Ana M. Molina
    10. Christos E. Kyriakopoulos
    11. Che Kai Tsao
    12. Leonard J. Appleman
    13. Benjamin A. Gartrell
    14. Arif Hussain
    15. Walter M. Stadler
    16. Neeraj Agarwal
    17. Russell K. Pachynski
    18. Thomas E. Hutson
    19. Hans J. Hammers
    20. Christopher W. Ryan
    21. Brant A. Inman
    22. Jack Mardekian
    23. Azah Borham
    24. Daniel J. George

  • Angiokines associated with targeted therapy outcomes in patients with non-clear cell renal cell carcinoma

    Clinical Cancer Research
    1. Andrew J. Armstrong
    2. Andrew B. Nixon
    3. Andrea Carmack
    4. Qian Yang
    5. Tim Eisen
    6. Walter M. Stadler
    7. Robert J. Jones
    8. Jorge A. Garcia
    9. Ulka N. Vaishampayan
    10. Joel Picus
    11. Robert E. Hawkins
    12. John D. Hainsworth
    13. Christian K. Kollmannsberger
    14. Theodore F. Logan
    15. Igor Puzanov
    16. Lisa M. Pickering
    17. Christopher W. Ryan
    18. Andrew Protheroe
    19. Daniel J. George
    20. Susan Halabi

  • A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609

    Cancer
    1. Sandip Pravin Patel
    2. Edward Mayerson
    3. Young Kwang Chae
    4. Jonathan Strosberg
    5. Jue Wang
    6. Bhavana Konda
    7. Jourdain Hayward
    8. Christine M. McLeod
    9. Helen X. Chen
    10. Elad Sharon
    11. Megan Othus
    12. Christopher W. Ryan
    13. Melissa Plets
    14. Charles D. Blanke
    15. Razelle Kurzrock

  • Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma

    Cell Reports Medicine
    1. Hui wen Lue
    2. Daniel S. Derrick
    3. Soumya Rao
    4. Ahna Van Gaest
    5. Larry Cheng
    6. Jennifer Podolak
    7. Samantha Lawson
    8. Changhui Xue
    9. Devin Garg
    10. Ralph White
    11. Christopher W. Ryan
    12. Justin M. Drake
    13. Anna Ritz
    14. Laura M. Heiser
    15. George V. Thomas

  • Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma

    Journal for immunotherapy of cancer
    1. Michael J. Wagner
    2. Megan Othus
    3. Sandip P. Patel
    4. Chris Ryan
    5. Ashish Sangal
    6. Benjamin Powers
    7. G. Thomas Budd
    8. Adrienne I. Victor
    9. Chung Tsen Hsueh
    10. Rashmi Chugh
    11. Suresh Nair
    12. Kirsten M. Leu
    13. Mark Agulnik
    14. Elad Sharon
    15. Edward Mayerson
    16. Melissa Plets
    17. Charles Blanke
    18. Howard Streicher
    19. Young Kwang Chae
    20. Razelle Kurzrock

  • A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

    Clinical Cancer Research
    1. Sandip P. Patel
    2. Megan Othus
    3. Young Kwang Chae
    4. Francis J. Giles
    5. Donna E. Hansel
    6. Preet Paul Singh
    7. Annette Fontaine
    8. Manisha H. Shah
    9. Anup Kasi
    10. Tareq Al Baghdadi
    11. Marc Matrana
    12. Zoran Gatalica
    13. W. Michael Korn
    14. Jourdain Hayward
    15. Christine McLeod
    16. Helen X. Chen
    17. Elad Sharon
    18. Edward Mayerson
    19. Christopher W. Ryan
    20. Melissa Plets
    21. Charles D. Blanke
    22. Razelle Kurzrock

  • A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma

    Oncologist
    1. Richard F. Riedel
    2. Karla V. Ballman
    3. Yao Lu
    4. Steven Attia
    5. Elizabeth T. Loggers
    6. Kristen N. Ganjoo
    7. Michael B. Livingston
    8. Warren Chow
    9. Jennifer Wright
    10. John H. Ward
    11. Daniel Rushing
    12. Scott H. Okuno
    13. Damon R. Reed
    14. David A. Liebner
    15. Vicki L. Keedy
    16. Leo Mascarenhas
    17. Lara E. Davis
    18. Christopher Ryan
    19. Denise K. Reinke
    20. Robert G. Maki

  • Deep Functional and Molecular Characterization of a High-Risk Undifferentiated Pleomorphic Sarcoma

    Sarcoma
    1. Noah E. Berlow
    2. Catherine S. Grasso
    3. Michael J. Quist
    4. Mingshan Cheng
    5. Regina Gandour-Edwards
    6. Brian S. Hernandez
    7. Joel E. Michalek
    8. Christopher Ryan
    9. Paul Spellman
    10. Ranadip Pal
    11. Lynn S. Million
    12. Mark Renneker
    13. Charles Keller

  • Feasibility of Treating Adults with Ewing or Ewing-Like Sarcoma with Interval-Compressed Vincristine, Doxorubicin, and Cyclophosphamide Alternating with Ifosfamide and Etoposide

    Oncologist
    1. Eric Lu
    2. Christopher W. Ryan
    3. Solange Bassale
    4. Jeong Youn Lim
    5. Lara E. Davis